| Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity Of GS 9350 (Medical News Today) |
|
|
Gilead Sciences, Inc. (Nasdaq: GILD) announced preclinical data and results from two Phase I studies for GS 9350, an investigational compound being developed as a pharmacoenhancing agent ("booster") to increase blood levels and allow once-daily dosing for certain medicines, including Gilead's investigational HIV integrase inhibitor, elvitegravir. |